Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 4 Not yet recruiting 31 enrolled China Medical University, China

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction

Timeline

Start: 2025-04-30
Primary completion: 2026-05-31
Completion: 2027-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Catequentinib	Small molecule	8 mg	Oral
Subject	Cisplatin	Other / unclassified	60 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	50 mg/m2	Intravenous
Subject	Tislelizumab	Monoclonal antibody	200 mg	Intravenous

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Summary

Timeline

Drugs

Indications